कंपनी का अवलोकन
Pediatrix Medical Group, Inc. operates within the Healthcare sector as a specialized provider of newborn, maternal-fetal, and pediatric subspecialty care services throughout the United States. The organization focuses on delivering critical clinical care to infants born prematurely or with complications, primarily utilizing hospital-based units such as Neonatal Intensive Care Units (NICUs). This entity functions within the broader Medical Care Facilities industry, a segment characterized by regulated environments and essential demand for specialized medical interventions. The company demonstrates significant scale with a total market capitalization of $1.77B and annual revenue reaching $1.91B, supported by an operational workforce of 4,280 employees. These valuation and revenue figures indicate that Pediatrix holds a substantial position in its niche, reflecting a robust market presence that supports its extensive network of specialized care facilities.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $1.91B, generating net income of $165.39M and an EBITDA of $252.91M during the same period. The gap between the $1.91B revenue and $165.39M net income reveals a significant cost structure, as expenses including cost of goods sold and operating costs consume approximately 91.4% of total revenue. Free cash flow stands at $190.33M, which provides the company with considerable financial flexibility to fund operations, service debt obligations, or invest in capital expenditures without immediate reliance on external financing. Profitability is further analyzed through three distinct margins: a gross margin of 25.8%, an operating margin of 11.1%, and a profit margin of 8.6%. The gross margin indicates the efficiency of direct service delivery, while the narrower operating and profit margins reflect the high fixed costs and regulatory expenses inherent in the medical care sector. Liquidity and leverage are assessed by comparing total cash of $499.72M against total debt of $634.61M, resulting in a debt-to-equity ratio of 73.29, which suggests a leveraged balance sheet typical for capital-intensive healthcare providers. Short-term liquidity is indicated by a current ratio of 1.66, suggesting the company holds sufficient current assets to cover its short-term liabilities with a comfortable buffer. Management effectiveness is quantified by a Return on Equity (ROE) of 20.3% and a Return on Assets (ROA) of 6.6%, where the higher ROE relative to ROA implies that the company is utilizing its equity base efficiently to generate profits, despite the asset-heavy nature of its operations.
मूल्यांकन आकलन
Valuation metrics for Pediatrix Medical Group, Inc. show a trailing P/E ratio of 11.00 and a forward P/E of 9.17. The difference between these ratios implies that the market expects earnings to grow or improve in the coming year, as investors are willing to pay a lower multiple for future earnings compared to historical performance. The price-to-book ratio is stated at 2.00, indicating that the company trades at a market premium of two times its book value, which often reflects intangible assets like brand reputation and specialized clinical capabilities that are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.93 and an EV/EBITDA of 7.37, suggesting the company is valued at slightly less than one dollar of sales for every dollar of revenue and generates significant operating earnings relative to its enterprise value. Price volatility and range are defined by a 52-week high of $24.99 and a 52-week low of $11.84. Based on the provided data points, the current trading price context can be analyzed relative to this historical range, though specific current price data is not included in the available facts; however, the wide range indicates significant price movement over the past year. The stock exhibits a beta of 0.72, which means its price volatility is lower than the broader market, offering a degree of stability compared to more aggressive healthcare equities.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of -1.7% year-over-year while earnings growth stands at 11.4%. This divergence indicates that earnings are growing substantially faster than revenue, implying improved operational efficiency, cost containment measures, or a shift in the product mix toward higher-margin services despite a slight contraction in total sales volume. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all of its net income back into the business rather than distributing cash to shareholders, a strategy often adopted by firms seeking to fund expansion or reduce leverage during periods of revenue headwinds. This reinvestment approach prioritizes capital appreciation over current income generation. Overall, the growth and income profile presents a scenario of earnings expansion driven by margin improvement rather than top-line volume growth, with capital returns directed toward internal growth initiatives instead of dividend payments.